Publications by authors named "M Chasseray"

Article Synopsis
  • Avelumab is a treatment approved for patients with advanced urothelial carcinoma (aUC) who did not experience disease progression after platinum-based chemotherapy, based on findings from the JAVELIN Bladder 100 trial.
  • The AVENANCE study included 595 patients and assessed the effectiveness and safety of avelumab as a maintenance therapy, revealing a median overall survival of 21.3 months.
  • The results demonstrated that avelumab is effective in this patient population, reinforcing its role in managing aUC in real-world settings.
View Article and Find Full Text PDF
Article Synopsis
  • - Patients with oligometastatic prostate cancer (having up to 5 metastases) generally have a better prognosis than those with more extensive disease, making this a crucial area for treatment investigation.
  • - The study investigates whether combining stereotactic body radiotherapy (SBRT) with the immune checkpoint inhibitor durvalumab can improve progression-free survival in these patients compared to SBRT alone.
  • - This multicenter phase II trial will evaluate various outcomes, including quality of life and immune response, by enrolling 96 participants over three years, aiming to provide insights into better treatment strategies for prostate cancer.
View Article and Find Full Text PDF

Purpose: During radiotherapy (RT) for prostate cancer (PCa), interfraction and intrafraction movements can lead to decreased target dose coverage and unnecessary over-exposure of organs at risk. New image-guided RT techniques accuracy allows planning target volume (PTV) margins reduction. We aim to assess the feasibility of a kilovoltage intrafraction monitoring (KIM) to track the prostate during RT.

View Article and Find Full Text PDF

To evaluate the occurrence of erectile dysfunction at 3 years (3yED) after prostate brachytherapy (BT) and to predict 3yED after treatment based on patients and treatments characteristics. From September 2007 to July 2015, 117 men with mild or no ED [International Index of Erectile Function (IIEF-5) > 16] underwent Iodine real-time ultrasound-guided low-dose rate BT to a total dose of 160 Gy for low-risk or favorable intermediate-risk prostate adenocarcinoma, and were followed prospectively during 3 years. Median age was 63 years (51-79).

View Article and Find Full Text PDF

The compatible interaction between the model plant, Arabidopsis thaliana, and the GMI1000 strain of the phytopathogenic bacterium, Ralstonia solanacearum, was investigated in an in vitro pathosystem. We describe the progression of the bacteria in the root from penetration at the root surface to the xylem vessels and the cell type-specific, cell wall-associated modifications that accompanies bacterial colonization. Within 6 days post inoculation, R.

View Article and Find Full Text PDF